Valuation: Assembly Biosciences, Inc.

Market Cap 671M 579M 544M 495M 931M 64.15B 946M 6.38B 2.49B 32.12B 2.52B 2.46B 107B P/E 2026 *
-12.8x
P/E 2027 * -10.8x
Enterprise Value 671M 579M 544M 495M 931M 64.15B 946M 6.38B 2.49B 32.12B 2.52B 2.46B 107B EV / Sales 2026 *
14.2x
EV / Sales 2027 * 20.8x
Free-Float
69.67%
Yield 2026 *
-
Yield 2027 * -
1 day+10.45%
1 week+23.99%
Current month+31.74%
1 month+23.76%
3 months+15.46%
6 months+24.08%
Current year-2.73%
1 week 26.24
Extreme 26.235
33.16
1 month 24.5
Extreme 24.5
33.16
Current year 21.8
Extreme 21.795
34.68
1 year 20.23
Extreme 20.23
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
47.28
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
6/4/26 A Free

Director

8,000 0.0514%
3/29/26 A Free

Chief Technology Officer

26,000 0.1671%
8/8/25 A BuyCompany 4,591,840 72.2409%
Change 5-day change 1-year change 3-year change Capi.($)
+10.45%+23.99%+30.03%+178.59% 671M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average +0.45%+2.84%+72.68%+118.03% 26.38B
Weighted average by Cap. -0.89%+0.65%+95.65%+133.07%

Financials

2026 *2027 *
Net sales 47.32M 40.87M 38.41M 34.93M 65.67M 4.52B 66.75M 450M 176M 2.27B 178M 174M 7.53B 32.25M 27.85M 26.17M 23.8M 44.75M 3.08B 45.49M 307M 120M 1.54B 121M 118M 5.13B
Net income -47.9M -41.37M -38.88M -35.36M -66.47M -4.58B -67.57M -456M -178M -2.29B -180M -176M -7.62B -62.81M -54.25M -50.98M -46.36M -87.16M -6.01B -88.6M -597M -234M -3.01B -236M -231M -9.99B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
14/08/26 $32.95 +10.02% 559,108
13/08/26 $29.95 +10.68% 729,236
12/08/26 $27.06 -0.77% 113,071
11/08/26 $27.27 +1.98% 213,415
10/08/26 $26.74 +0.22% 105,718
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
32.95USD
Average target price
50.00USD
Spread / Average Target
+51.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock